SCOTUS to hear out Teva on Copaxone delay

Share this article:

Teva announced today that the Supreme Court will hear its appeal in a move to delay generic competition for the drugmaker's multiple sclerosis treatment Copaxone. Teva hopes to extend the drug's patent life through September 2015. Its current patent for Copaxone is set to expire in May of this year.

In January FDA approved a new version of Copaxone that allows patients to take the drug three times a week rather than daily. The drugmaker, according to Reuters, says that it believes 45% of regular Copaxone patients will switch to the new form of the drug.  Leerink Partners analyst Jason Gerberry said he expects that 25% of current Copaxone patients will be switched by June, about 33% by year end and 40% in two years, also reported by Reuters.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Genentech shift could prove costly for hospitals

Genentech will use specialty distributors rather than wholesalers, hospitals pharmacy directors have learned.

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies